Literature DB >> 2382846

Pharmacokinetics of long-term propofol infusion used for sedation in ICU patients.

J Albanese1, C Martin, B Lacarelle, P Saux, A Durand, F Gouin.   

Abstract

The pharmacokinetics of propofol were determined in nine patients (seven men, two women, (mean +/- SD) 55.8 +/- 21.2 yr, 65.2 +/- 8 kg) requiring prolonged mechanical ventilation of their lungs. After an initial dose of 1-3 mg/kg, propofol was administered iv at 3 mg/kg/h for 72 h. Arterial blood samples were collected at selected times during and up to 72 h after infusion. Propofol whole blood concentrations were determined by high-performance liquid chromatography with fluorescence detection. Individual pharmacokinetic parameters were estimated by noncompartmental analysis. Derived pharmacokinetic parameters showed a long terminal phase (T1/2 = 1878 +/- 672 min), a large volume of distribution at steady state (Vdss = 1666 +/- 756 l), and a high total body clearance (Cl = 1.57 +/- 0.56 l/min). While the propofol terminal elimination half-life is longer than that previously reported, emergence from sedation after prolonged administration will be governed by both redistribution mechanisms arising from the large distribution volumes and elimination from the body.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2382846     DOI: 10.1097/00000542-199008000-00004

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  28 in total

1.  Use of propofol to control refractory involuntary movements.

Authors:  David V Lardizabal; Vivek Sabharwal; Ali Jahan; Samay Jain; Christopher Snyder; Marc J Popovich; Michael DeGeorgia
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

Review 2.  Pharmacology of drugs frequently used in ICUs: midazolam and flumazenil.

Authors:  R Amrein; W Hetzel
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

Review 3.  Sedation for critically ill or injured adults in the intensive care unit: a shifting paradigm.

Authors:  Derek J Roberts; Babar Haroon; Richard I Hall
Journal:  Drugs       Date:  2012-10-01       Impact factor: 9.546

Review 4.  [Brain death diagnosis after sedation with propofol or sufentanil. Recommendations for the usage of toxicological analytics].

Authors:  U Walter; U Brüderlein; M Gloger; S Mann; U Walther
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-09-26       Impact factor: 0.840

5.  Intravenous anesthetic propofol binds to 5-lipoxygenase and attenuates leukotriene B4 production.

Authors:  Toshiaki Okuno; Sophia Koutsogiannaki; Mai Ohba; Matthew Chamberlain; Weiming Bu; Fu-Yan Lin; Roderic G Eckenhoff; Takehiko Yokomizo; Koichi Yuki
Journal:  FASEB J       Date:  2017-01-09       Impact factor: 5.191

6.  Acute gonadotroph and somatotroph hormonal suppression after traumatic brain injury.

Authors:  Justin Wagner; Joshua R Dusick; David L McArthur; Pejman Cohan; Christina Wang; Ronald Swerdloff; W John Boscardin; Daniel F Kelly
Journal:  J Neurotrauma       Date:  2010-06       Impact factor: 5.269

7.  Total body propofol clearance (TBPC) after living-donor liver transplantation (LDLT) surgery is decreased in patients with a long warm ischemic time.

Authors:  Wael S Al-Jahdari; Fumio Kunimoto; Shigeru Saito; Koujirou Yamamoto; Hiroshi Koyama; Ryuya Horiuchi; Fumio Goto
Journal:  J Anesth       Date:  2006       Impact factor: 2.078

Review 8.  Propofol in patients with cardiac disease.

Authors:  N R Searle; P Sahab
Journal:  Can J Anaesth       Date:  1993-08       Impact factor: 5.063

9.  Propofol emulsion reduces proliferative responses of lymphocytes from intensive care patients.

Authors:  C O Pirttikangas; J Perttilä; M Salo
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

10.  Propofol shares the binding site with isoflurane and sevoflurane on leukocyte function-associated antigen-1.

Authors:  Koichi Yuki; Weiming Bu; Jin Xi; Motomu Shimaoka; Roderic Eckenhoff
Journal:  Anesth Analg       Date:  2013-08-19       Impact factor: 5.108

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.